EUVIMEDEUVIMED entdecken
Open Access

Arginine vasopressin deficiency and conivaptan (a V1a–V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis

Yesenia Danyeli Navarro-Gonzalez, Javier Ventura-Juarez, Martín Humberto Muñoz-Ortega iD, Daniel González-Blas, Argelia Calvillo-Robedo, Manuel-Enrique Avila-Blanco, Fernando Valdez-Urias, Andrés Quintanar-Stephano

International Journal of Experimental Pathology · 2023-08 · 104 (4) · 209-222

DOI: 10.1111/iep.12476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Experimental Pathology, online erschienen am 25.03.2023. Verfasst von Yesenia Danyeli Navarro-Gonzalez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Fisiología y Farmacología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, Mexico. Hauptthemen laut MEDLINE: Receptors, Vasopressin, Diabetes Insipidus, Neurogenic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Consejo Nacional de Ciencia y Tecnología, Universidad Autónoma de Aguascalientes, Mexico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arginine vasopressin (AVP) is a naturally occurring hormone synthesized in the hypothalamus. AVP demonstrates pro‐fibrotic effects as it stimulates hepatic stellate cells to secrete transforming growth factor‐β (TGF‐β) and collagen. Previous work in liver cirrhotic (CCL 4 ‐induced) hamsters demonstrated that AVP deficiency induced by neurointermediate pituitary lobectomy (NIL) can restore liver function. Therefore, we hypothesized that liver fibrosis would decrease in portocaval anastomosis (PCA) rats, which model chronic liver diseases, when they are treated with the V1a–V2 AVP receptor antagonist conivaptan (CV). In this study, changes in liver histology and gene expression were analysed in five experimental groups: control, PCA, NIL, PCA + NIL and PCA + CV, with NIL surgery or CV treatment administered 8 weeks after PCA surgery. Body weight gain was assessed on a weekly basis, and serum liver function, liver weight and liver glycogen content were assessed following euthanasia. Most PCA‐induced phenotypes were reverted to normal levels following AVP‐modelled deficiency, though hypoglycemia and ammonium levels remained elevated in the PCA + CV group. Liver histopathological findings showed a significant reversal in collagen content, less fibrosis in the triad and liver septa and increased regenerative nodules. Molecular analyses showed that the expression of fibrogenic genes (TGF‐β and collagen type I) decreased in the PCA + CV group. Our findings strongly suggest that chronic NIL or CV treatment can induce a favourable microenvironment to decrease liver fibrosis and support CV as an alternative treatment for liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, VasopressinDiabetes Insipidus, NeurogenicCricetinaeRatsAnimalsAntidiuretic Hormone Receptor AntagonistsArginine VasopressinLiver CirrhosisAnastomosis, SurgicalArginineBenzazepines

Stichwörter der Autor:innen

arginine vasopressinconivaptancytokinesliver fibrosisportocaval anastomosis

Substanzen

Receptors, VasopressinAntidiuretic Hormone Receptor AntagonistsArginine VasopressinArginineconivaptanBenzazepines

Autor:innen und Institutionen

  • Departamento de Fisiología y Farmacología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, Mexico.
  • Departamento de Morfología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, Mexico.
  • Departamento de Química, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, Mexico.
  • Departamento de Patología, Hospital General ISSSTE, Aguascalientes, Mexico.

ORCID-Profile: Martín Humberto Muñoz-Ortega

Förderung

  • Consejo Nacional de Ciencia y Tecnología
  • Universidad Autónoma de Aguascalientes, Mexico

Zitieren

APA

Navarro-Gonzalez, Y. D., Ventura-Juarez, J., Muñoz-Ortega, M. H., González-Blas, D., Calvillo-Robedo, A., Avila-Blanco, M. E., Valdez-Urias, F., & Quintanar-Stephano, A. (2023). Arginine vasopressin deficiency and conivaptan (a V1a–V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis. International Journal of Experimental Pathology, 104(4), 209-222. https://doi.org/10.1111/iep.12476

Vancouver

Navarro-Gonzalez YD, Ventura-Juarez J, Muñoz-Ortega MH, González-Blas D, Calvillo-Robedo A, Avila-Blanco ME, et al. Arginine vasopressin deficiency and conivaptan (a V1a–V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis. International Journal of Experimental Pathology. 2023;104(4):209-222. doi:10.1111/iep.12476

BibTeX
@article{NavarroGonzalez2023,
  author = {Navarro-Gonzalez, Yesenia Danyeli and Ventura-Juarez, Javier and Muñoz-Ortega, Martín Humberto and González-Blas, Daniel and Calvillo-Robedo, Argelia and Avila-Blanco, Manuel-Enrique and Valdez-Urias, Fernando and Quintanar-Stephano, Andrés},
  title = {Arginine vasopressin deficiency and conivaptan (a V1a–V2 receptor antagonist) treatment reverses liver damage and fibrosis in rats with chronic portocaval anastomosis},
  journal = {International Journal of Experimental Pathology},
  year = {2023},
  volume = {104},
  number = {4},
  pages = {209--222},
  doi = {10.1111/iep.12476}
}
Kostenlos starten →